BET bromodomain proteins are required for glioblastoma cell proliferation

Epigenetics

Volumn 9, Issue 4, 2014, Pages 611-620

  Pastori, Chiara ^a   Daniel, Mark ^a   Penas, Clara ^a   Volmar, Claude Henry ^a   Johnstone, Andrea L ^a   Brothers, Shaun P ^a   Graham, Regina M ^a   Allen, Bryce ^a   Sarkaria, Jann N ^b   Komotar, Ricardo J ^a   Wahlestedt, Claes ^a   Ayad, Nagi G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Bromodomain; Epigenetics; Glioblastoma; Histone acetylation mimics; Histones; Stem cells; Temozolomide

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BROMODOMAIN AND EXTRA TERMINAL DOMAIN PROTEIN; BROMODOMAIN PROTEIN 2; BROMODOMAIN PROTEIN 3; BROMODOMAIN PROTEIN 4; HISTONE; I BET 151; LYSINE ACETYLATED HISTONE; TEMOZOLOMIDE; TOCRIS; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; 7 (3,5 DIMETHYL 4 ISOXAZOLYL) 1,3 DIHYDRO 8 METHOXY 1 [1 (2 PYRIDINYL)ETHYL] 2H IMIDAZO[4,5 C]QUINOLIN 2 ONE; BRD2 PROTEIN, HUMAN; BRD4 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PHYLOGENETIC TREE; PROPIDIUM IODIDE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CANCER TRANSPLANTATION; CASE CONTROL STUDY; CELL CYCLE CHECKPOINT; DRUG EFFECTS; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; GLIOBLASTOMA; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HETEROGRAFTS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS;

EID: 84899131911     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.27906     Document Type: Article

References (30)

1. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150:12-27; PMID:22770212; http://dx.doi.org/10.1016/j. cell.2012.06.013
2. Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med 2012; 367:647-57; PMID:22894577; http://dx.doi. org/10.1056/NEJMra1112635
3. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011; 478:529-33; PMID:21964340; http://dx.doi.org/10.1038/ nature10509
4. Yang Z, Yik JH, Chen R, He N, Jang MK, Ozato K, Zhou Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell 2005; 19:535-45; PMID:16109377; http://dx.doi.org/10.1016/j. molcel.2005.06.029
5. Yang XJ. Multisite protein modification and intramolecular signaling. Oncogene 2005; 24:1653-62; PMID:15744326; http://dx.doi.org/10.1038/ sj.onc.1208173
6. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Nature 2010; 468:1067-73; PMID:20871596; http://dx.doi.org/10.1038/ nature09504
7. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H, et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010; 468:1119-23; PMID:21068722; http://dx.doi.org/10.1038/ nature09589
8. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478:524-8; PMID:21814200; http://dx.doi. org/10.1038/nature10334
9. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146:904-17; PMID:21889194; http://dx.doi.org/10.1016/j. cell.2011.08.017
10. Belkina AC, Blanton WP, Nikolajczyk BS, Denis GV. The double bromodomain protein Brd2 promotes B cell expansion and mitogenesis. J Leukoc Biol 2013; Forthcoming; PMID:24319289; http://dx.doi. org/10.1189/jlb.1112588
11. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DM. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012; 120:2843-52; PMID:22904298; http:// dx.doi.org/10.1182/blood-2012-02-413021
12. Belkina AC, Nikolajczyk BS, Denis GV. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol 2013; 190:3670-8; PMID:23420887; http://dx.doi. org/10.4049/jimmunol.1202838
13. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459-66; PMID:19269895; http:// dx.doi.org/10.1016/S1470-2045(09)70025-7
14. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95:190-8; PMID:11780887; http:// dx.doi.org/10.3171/jns.2001.95.2.0190
15. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488:522-6; PMID:22854781; http:// dx.doi.org/10.1038/nature11287
16. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, Fell HP, Ferree S, George RD, Grogan T, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008; 26:317-25; PMID:18278033; http://dx.doi.org/10.1038/nbt1385
17. Benjamini YaH. Y. Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing. J R Stat Soc, B 1995; 57:289-300
18. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, Kashiwagi S, Fukami K, Miyata T, Miyoshi H, et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008; 132:487-98; PMID:18267078; http://dx.doi. org/10.1016/j.cell.2007.12.033
19. Seal J, Lamotte Y, Donche F, Bouillot A, Mirguet O, Gellibert F, Nicodeme E, Krysa G, Kirilovsky J, Beinke S, et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett 2012; 22:2968-72; PMID:22437115; http://dx.doi.org/10.1016/j.bmcl.2012.02.041
20. Greenwald RJ, Tumang JR, Sinha A, Currier N, Cardiff RD, Rothstein TL, Faller DV, Denis GV. E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood 2004; 103:1475-84; PMID:14563639; http://dx.doi.org/10.1182/ blood-2003-06-2116
21. Sinha A, Faller DV, Denis GV. Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. Biochem J 2005; 387:257-69; PMID:15548137; http://dx.doi.org/10.1042/BJ20041793
22. Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA, Thompson RC, Muller S, Knapp S, Wang J. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res 2013; 19:1748-59; PMID:23403638; http://dx.doi.org/10.1158/1078-0432.CCR-12-3066
23. Wang H, Shimizu E, Tang YP, Cho M, Kyin M, Zuo W, Robinson DA, Alaimo PJ, Zhang C, Morimoto H, et al. Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain. Proc Natl Acad Sci U S A 2003; 100:4287-92; PMID:12646704; http:// dx.doi.org/10.1073/pnas.0636870100
24. Merrick KA, Wohlbold L, Zhang C, Allen JJ, Horiuchi D, Huskey NE, Goga A, Shokat KM, Fisher RP. Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation. Mol Cell 2011; 42:624-36; PMID:21658603; http:// dx.doi.org/10.1016/j.molcel.2011.03.031
25. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA. Selective inhibition of tumor oncogenes by disruption of superenhancers. Cell 2013; 153:320-34; PMID:23582323; http://dx.doi.org/10.1016/j.cell.2013.03.036
26. Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, Sebastiani P, Margolis DM, Montano M. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 2012; 92:1147-54; PMID:22802445; http://dx.doi. org/10.1189/jlb.0312165
27. Clarke J, Penas C, Pastori C, Komotar RJ, Bregy A, Shah AH, Wahlestedt C, Ayad NG. Epigenetic pathways and glioblastoma treatment. Epigenetics 2013; 8:785-95; PMID:23807265; http://dx.doi. org/10.4161/epi.25440
28. Carlson BL, Pokorny JL, Schroeder MA, Sarkaria JN. Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol 2011; Chapter 14:Unit 14 6.
29. Smith A, Simanski S, Fallahi M, Ayad NG. Redundant ubiquitin ligase activities regulate wee1 degradation and mitotic entry. Cell Cycle 2007; 6:2795-9; PMID:18032919; http://dx.doi. org/10.4161/cc.6.22.4919
30. Liu L, Zhen XT, Denton E, Marsden BD, Schapira M. ChromoHub: a data hub for navigators of chromatinmediated signalling. Bioinformatics 2012; 28:2205-6; PMID:22718786; http://dx.doi.org/10.1093/ bioinformatics/bts340